0%
Print report
Variant interpretation report

BRCA1 c.231G>A, p.Thr77=

NM_007294.4:c.231G>A NP_009225.1:p.(Thr77=) Synonymous · exon 5 View identifiers
Classification
Likely benign

Variant description:

The BRCA1 NM_007294.4:c.231G>A (NP_009225.1:p.(Thr77=)) synonymous variant has previously been reported in somatic cancers (COSMIC; COSV58792582, n = 4 times). Based on available guidelines, this variant is considered to be Likely Benign. This variant is considered to be Likely Benign by the VCEP (Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA); ClinVar ID 142611).

Five-step scale from benign to pathogenic. This variant is likely benign. Select a step to read what it means.

Likely benign.A likely benign classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About BRCA1

BRCA1 encodes a large nuclear protein that helps maintain genomic stability by coordinating the repair of DNA double-strand breaks through homologous recombination, and it also regulates transcription and the cell cycle. It acts as a tumor suppressor, working with proteins such as RAD51, BRCA2, BARD1, and PALB2 to preserve genome integrity. Inherited alterations in BRCA1 cause hereditary breast and ovarian cancer syndrome, with elevated risks of breast, ovarian, prostate, and pancreatic cancers, and biallelic loss underlies a rare form of Fanconi anemia. Because BRCA1-driven tumors rely on impaired DNA repair, they are treatable with PARP inhibitors.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen BRCA1 VCEP v1.2. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 4
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 4
BP4Supporting
BP4 · supporting

Met at Supporting: SpliceAI maximum delta score 0.052 is below the VCEP BP4 threshold of 0.1 for a silent variant inside the RING domain.

BP5Supporting
BP5 · supporting

Met at Supporting: Li et al. report LR 0.354419980849377, satisfying 0.354419980849377 ≤ 0.48 and >0.23 under the VCEP BP5 range.

BP6Supporting
BP6 · supporting

Not applicable: the ENIGMA VCEP prohibits BP6, so no reputable-source benign report can be used for this criterion.

BP7Supporting
BP7 · supporting

Met at Supporting: the silent p.(Thr77=) variant meets BP4 with SpliceAI maximum delta score 0.052, satisfying the VCEP BP7 condition.

Recorded classification: Likely benign

Likely Benign: BP4, BP5, and BP7 are met at Supporting strength under the ENIGMA BRCA1 VCEP Table 3 rule requiring at least two Supporting benign criteria.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
6 / 1,613,712 alleles

gnomAD v4.1: 6 / 1,613,712 alleles. Recorded AF 3.71814e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98102e-06; MAF= 0.00040%, 1/251192 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 2.89118e-05; MAF= 0.00289%, 1/34588 alleles, homozygotes = 0).

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

SpliceAI score
0.052 maximum delta

Recorded SpliceAI maximum delta score: 0.052. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
8 reported laboratory submissions

7 Likely benign · 1 Likely Benign. ClinVar API review status: reviewed by expert panel.

No screenshot for this evidence
Functional evidence
Not recorded

No standalone functional evidence summary is recorded in evidence_summary.functional.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
4 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV58792582, n = 4 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen BRCA1 VCEP v1.2, with the data and sources behind each one.

28 criteria with recorded statuses: 4 met · 5 not met · 8 not assessed · 11 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

PS2 and PM6 are explicitly excluded by the ENIGMA BRCA1 VCEP. PP1 and BS4 remain not assessed because no quantitative family segregation or non-segregation evidence is available for this variant.

The only met criterion in this group is BP5 at Supporting strength, based on the exact Li et al. 2020 clinical-history LR row for BRCA1 c.231G>A.

PP4 is not met because the same LR is below the VCEP pathogenicity threshold; PS4 has no qualifying variant-specific case-control evidence; PP5 and BP6 are prohibited by the VCEP.

For this synonymous BRCA1 variant at p.(Thr77=) within the RING domain, the governing ENIGMA VCEP rules yield BP4_Supporting and BP7_Supporting from SpliceAI maximum delta score 0.052, while PP3 is not met because its splice threshold is 0.2.

Met · 4

BP4 SupportingVCEPMet at Supporting: SpliceAI maximum delta score 0.052 is below the VCEP BP4 threshold of 0.1 for a silent variant inside the RING domain. Details ▾Hide ▴
Reasoning

The variant is synonymous and encodes p.(Thr77=), placing it at BRCA1 residue 77 within the VCEP-defined RING functional domain (aa 2-101). The VCEP BP4 rule specifically covers silent variants inside a clinically important functional domain when SpliceAI is <=0.1. The maximum SpliceAI delta score is 0.052, which meets the <=0.1 requirement; BP4 is therefore met at Supporting strength. No exact c.231G>A, p.Thr77=, or p.T77= entry was found in the searched VCEP supplementary or assay tables, and no exact mention was found in the Houdayer paper.

VCEP rule
Silent variant inside a (potentially) clinically important functional domain, if no predicted impact via splicing (SpliceAI ≤0.1).
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 CSPEC BP4 rule: silent variants inside a potentially clinically important functional domain qualify when SpliceAI <=0.1.
  • The VCEP defines the BRCA1 RING functional domain as amino acids 2-101; p.(Thr77=) is within this domain.
  • Case SpliceAI result for NM_007294.4:c.231G>A: maximum delta score 0.052 (DS_DL 0.052), meeting the VCEP BP4 threshold.
  • Variant normalization identifies NM_007294.4:c.231G>A as synonymous, NP_009225.1:p.(Thr77=).
  • SupplementaryTables_V1.2_2024-11-18.xlsx.txt and Specifications_Table9_V1.2_2024-11-18.xlsx.txt were searched under c.231G>A, p.Thr77=, and p.T77=; neither contained an exact matching row.
  • PMID_22505045_Houdayer_2012_HumMutat.pdf.txt was searched for the variant notations and contained no exact match.
Still missing
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= mention was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BP5 SupportingVCEPMet at Supporting: Li et al. report LR 0.354419980849377, satisfying 0.354419980849377 ≤ 0.48 and >0.23 under the VCEP BP5 range. Details ▾Hide ▴
Reasoning

The ENIGMA VCEP restricts BP5 to combined multifactorial clinical likelihood ratios against pathogenicity. The exact BRCA1 row for c.231G>A in Li et al. 2020 Supplementary Table 3 reports LOG(LR) = -0.4504818022251129 and LR = 0.354419980849377. The VCEP BP5 Supporting range is LR ≤0.48 to >0.23:1; explicitly, 0.354419980849377 ≤ 0.48? yes, and 0.354419980849377 > 0.23? yes. BP5 Supporting is met.

VCEP rule
Use ONLY to capture combined LR against pathogenicity, based on multifactorial likelihood clinical data. BP5 - LR ≤0.48 to >0.23:1 Not applicable for co-observation: cases with pathogenic variants in two (or more) different known breast–ovarian cancer risk genes have no specific phenotype.
Evidence considered
  • Li et al. 2020 BRCA1 clinical-history LR table, Sheet1, matching row BRCA1 c.231G>A: LOG(LR) = -0.4504818022251129, N_Probands = 1, LR = 0.354419980849377.
  • ENIGMA BRCA1/2 VCEP Specifications v1.2, BP5 Supporting rule: BP5 - LR ≤0.48 to >0.23:1.
  • Explicit threshold comparison: 0.354419980849377 ≤ 0.48? yes; 0.354419980849377 > 0.23? yes.
Sources
BP6 SupportingVCEPNot applicable: the ENIGMA VCEP prohibits BP6, so no reputable-source benign report can be used for this criterion. Details ▾Hide ▴
Reasoning

Expert panel Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) classified as Likely benign.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ENIGMA BRCA1/2 VCEP CSPEC BP6 entry states: This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
  • The governing specification Table 1 lists BP6 as Do not use.
  • ClinVar expert panel classification
Sources
BP7 SupportingVCEPMet at Supporting: the silent p.(Thr77=) variant meets BP4 with SpliceAI maximum delta score 0.052, satisfying the VCEP BP7 condition. Details ▾Hide ▴
Reasoning

The variant is a silent substitution at p.(Thr77=), within the VCEP-defined BRCA1 RING domain (aa 2-101). The VCEP assigns BP7 at Supporting strength to a silent variant inside a clinically important functional domain if BP4 is met. BP4 is met because the SpliceAI maximum delta score is 0.052, no greater than 0.1; BP7 is consequently met at Supporting strength. The VCEP explicitly states that BP7 is applied in addition to BP4 for silent variants. No exact c.231G>A, p.Thr77=, or p.T77= entry was found in the searched VCEP tables or Houdayer paper.

VCEP rule
Silent variant inside a (potentially) clinically important functional domain, IF BP4 met.
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 CSPEC BP7 rule: silent variant inside a potentially clinically important functional domain qualifies if BP4 is met.
  • The VCEP defines the BRCA1 RING functional domain as amino acids 2-101; p.(Thr77=) is within this domain.
  • BP4 is met from the case SpliceAI maximum delta score of 0.052, which is <=0.1 under the VCEP rule.
  • The VCEP states that BP7 is applied in addition to BP4 for silent variants.
  • SupplementaryTables_V1.2_2024-11-18.xlsx.txt and Specifications_Table9_V1.2_2024-11-18.xlsx.txt were searched under c.231G>A, p.Thr77=, and p.T77=; neither contained an exact matching row.
  • PMID_22505045_Houdayer_2012_HumMutat.pdf.txt was searched for the variant notations and contained no exact match.
Still missing
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= mention was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources

Not met · 5 · evaluated, threshold not reached

PS4 VCEPNot met: no variant-specific case-control counts, odds ratio, p-value, or confidence interval establish the VCEP requirements of p≤0.05, OR≥4, and lower CI>2.0. Details ▾Hide ▴
Reasoning

The ENIGMA VCEP requires a case-control study with p-value ≤0.05, OR ≥4, and a lower confidence limit excluding 2.0. No variant-specific case-control counts, odds ratio, confidence interval, or p-value were found for NM_007294.4:c.231G>A (NP_009225.1:p.(Thr77=)/p.(T77=)). The literature_pass packet has an empty ai_classified_papers list; its PS4 candidate references are general clinical or reporting resources, and the available paper extraction for PMID:23788249 does not mention BRCA1 or this variant. Therefore the VCEP PS4 requirement is not met.

VCEP rule
The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls. Case-control studies; p-value ≤0.05 and OR ≥4 (lower confidence interval excludes 2.0). See Appendix F for details.
Evidence considered
  • ENIGMA BRCA1/2 VCEP Specifications v1.2, PS4 rule: case-control studies require p-value ≤0.05 and OR ≥4, with the lower confidence interval excluding 2.0.
  • literature_pass.json records ai_classified_papers as an empty list and indexes PMID:20301425, PMID:23788249, PMID:25394175, and PMID:26389258 as PS4 candidates.
  • PMID:23788249 paper extraction searched for BRCA1 c.231G>A and NP_009225.1:p.(T77=), found no variant mention, and reported no variant-specific case observations or population data.
Still missing
  • No variant-specific case-control dataset with affected and control counts, OR, confidence interval, and p-value was identified.
  • The PS4 candidate references PMID:20301425, PMID:23788249, PMID:25394175, and PMID:26389258 did not provide variant-specific case-control evidence in the available packet; PMID:23788249 was explicitly extracted as not mentioning BRCA1 or this variant.
Sources
PM2 VCEPNot met: gnomAD v2.1 non-cancer exomes contains one allele (AF 4.22504e-06), and the VCEP says a single observation is not informative. Details ▾Hide ▴
Reasoning

The ENIGMA PM2_Supporting rule requires absence from controls in both specified outbred datasets, with average regional read depth at least 25. c.231G>A is present once in gnomAD v2.1 non-cancer exomes (AF 4.225042672930997e-06; 1/236684 alleles; 0 homozygotes), while it is absent from gnomAD v3.1 non-cancer. The VCEP Appendix G explicitly states that observing a variant only once in an outbred gnomAD population is not informative and that no code should be applied; regional read depth is also not reported.

VCEP rule
Absent from controls in an outbred population, from gnomAD v2.1 (non-cancer, exome only subset) and gnomAD v3.1 (non-cancer). Region around the variant must have an average read depth ≥25. See Appendix G for details.
Evidence considered
  • gnomAD v2.1 non-cancer exomes: c.231G>A is present at AF 4.225042672930997e-06, 1/236684 alleles, with 0 homozygotes.
  • gnomAD v3.1 non-cancer: c.231G>A is absent.
  • ENIGMA Appendix G states that observation of a variant only once in a gnomAD outbred population was not informative and that no code should be applied; it also requires read depth >25 for PM2_Supporting.
Still missing
  • Regional average read depth is not reported, although the VCEP requires at least 25 for PM2_Supporting.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt; only c.231G>C and c.231G>T entries were found.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
PP3 VCEPNot met: SpliceAI maximum delta score 0.052 is below the VCEP PP3 threshold of 0.2 for predicted splicing in silent variants. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_007294.4:c.231G>A; p.(Thr77=)) and therefore falls within the VCEP's PP3 splicing path. The governing rule requires SpliceAI >=0.2 for PP3 on silent variants. The available SpliceAI maximum delta score is 0.052 (DS_DL 0.052), below that threshold, so PP3 is not met. No exact c.231G>A, p.Thr77=, or p.T77= entry was found in the governing supplementary lookup file or the searched VCEP assay tables; the c.231G>C and c.231G>T rows are different variants and were not used.

VCEP rule
Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions.
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 CSPEC PP3 rule: predicted splicing applies to silent variants at SpliceAI >=0.2.
  • Case SpliceAI result for NM_007294.4:c.231G>A: DS_AG 0.001, DS_AL 0.008, DS_DG 0.004, DS_DL 0.052; maximum delta score 0.052.
  • Variant normalization identifies NM_007294.4:c.231G>A as synonymous, NP_009225.1:p.(Thr77=).
  • SupplementaryTables_V1.2_2024-11-18.xlsx.txt was searched for c.231G>A, p.Thr77=, and p.T77=; only different c.231G>C and c.231G>T rows were found.
  • Specifications_Table9_V1.2_2024-11-18.xlsx.txt was searched for c.231G>A, p.Thr77=, and p.T77=; no exact matching row was found.
  • PMID_22505045_Houdayer_2012_HumMutat.pdf.txt was searched for c.231G>A, p.Thr77=, p.T77=, and T77; no exact variant mention was found.
Still missing
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= mention was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
PP4 VCEPNot met: Li et al. report LR 0.354419980849377, and 0.354419980849377 ≥ 2.08? no, below the VCEP PP4 Supporting threshold. Details ▾Hide ▴
Reasoning

The ENIGMA VCEP restricts PP4 to combined multifactorial clinical likelihood ratios toward pathogenicity. The exact BRCA1 row for c.231G>A in Li et al. 2020 Supplementary Table 3 reports LOG(LR) = -0.4504818022251129 and LR = 0.354419980849377. The Supporting PP4 threshold is LR ≥2.08:1; explicitly, 0.354419980849377 ≥ 2.08? no. The value is below the PP4 supporting threshold and therefore PP4 is not met.

VCEP rule
Breast cancer is very common and has a high degree of genetic heterogeneity (caused by pathogenic variants in numerous genes). Use ONLY to capture combined LR towards pathogenicity, based on multifactorial likelihood clinical data. PP4 - LR ≥2.08:1  See Specifications Table7 and Appendix B for details.
Evidence considered
  • Li et al. 2020 BRCA1 clinical-history LR table, Sheet1, matching row BRCA1 c.231G>A: LOG(LR) = -0.4504818022251129, N_Probands = 1, LR = 0.354419980849377.
  • ENIGMA BRCA1/2 VCEP Specifications v1.2, PP4 Supporting rule: PP4 - LR ≥2.08:1.
  • Explicit threshold comparison: 0.354419980849377 ≥ 2.08? no.
Sources
BP1 VCEPNot met: SpliceAI max delta 0.052 meets the ≤0.1 condition, but residue 77 is inside the BRCA1 RING domain spanning aa 2-101. Details ▾Hide ▴
Reasoning

The variant is a silent substitution and has no predicted splicing effect (SpliceAI maximum delta 0.052, meeting the ≤0.1 condition), but residue 77 lies inside the VCEP-defined BRCA1 RING functional domain (aa 2-101). BP1_Strong requires the silent substitution to be outside a clinically important functional domain, so the criterion is not met.

VCEP rule
Apply BP1_Strong for silent substitution, missense or in-frame insertion, deletion or delins variants outside a (potentially) clinically important functional domain AND no splicing predicted (SpliceAI ≤0.1). ... As justified in the appendices, (potentially) clinically important functional domains are defined as: BRCA1 RING aa 2-101; BRCA1 coiled-coil aa 1391-1424; BRCA1 BRCT repeats aa 1650-1857.
Evidence considered
  • The variant is synonymous at residue 77: NM_007294.4:c.231G>A, NP_009225.1:p.(Thr77=).
  • SpliceAI maximum delta score is 0.052, satisfying the VCEP's no-splicing condition of SpliceAI≤0.1.
  • The VCEP defines the BRCA1 RING functional domain as aa 2-101; residue 77 is therefore inside the domain, failing BP1's required outside-domain condition.
Sources

Not assessed · 8 · no assessment recorded

PS3 VCEPNot assessed: no exact c.231G>A functional-assay entry or pre-assigned PS3 code was found in the governing ENIGMA datasets. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_007294.4:c.231G>A; p.(Thr77=)/p.(T77=)). The governing ENIGMA functional-assay sources were searched under c.231G>A, p.Thr77=, and p.T77=. Specifications Table 9 contains no exact entry for this variant, and Supplementary Tables ST4 contains no exact functional-assay row. The nearby but different synonymous variants c.231G>C and c.231G>T are not evidence for c.231G>A and were not transferred. The VCEP PS3 rule requires well-established functional studies supportive of a damaging effect, with protein-only or combined mRNA/protein measurement; the available governing record does not provide variant-specific assay evidence or a pre-assigned PS3 code for c.231G>A. Therefore PS3 cannot be assessed from the permitted evidence.

VCEP rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect. Apply PS3 for assays measuring effect via protein only OR mRNA and protein combined. See Specifications Table 9 for code recommendations from calibrated published assays.
Evidence considered
  • Specifications Table 9, searched rows for c.231G>A, p.Thr77=, and p.T77=: no exact row; the table states that listed calibrated functional results carry code recommendations, but this variant is not listed.
  • Supplementary Tables ST4, searched rows for c.231G>A, p.Thr77=, and p.T77=: no exact row. Nearby distinct variants c.231G>C (FUNC) and c.231G>T (LOF) were not used for this variant.
  • Specifications v1.2, PS3 functional-assay rule: damaging-effect studies are assessed under PS3 when the assay measures protein alone or mRNA and protein combined; no qualifying variant-specific result was available.
  • Appendices v1.2, Appendix E / PS3 and BS3 code-use material: functional evidence must be evaluated using the VCEP functional-assay process and calibrated data; no exact c.231G>A result was identified.
  • HUMU-40-1557-s001, searched for c.231G>A and related synonymous notation: no exact functional-assay classification row was identified.
Still missing
  • No exact c.231G>A entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt after searches for c.231G>A, p.Thr77=, and p.T77=.
  • No exact c.231G>A entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt after searches for c.231G>A, p.Thr77=, and p.T77=.
  • No variant-specific protein-only or combined mRNA/protein assay result for c.231G>A was identified in the permitted VCEP materials.
Sources
PM3 VCEPNot assessed: no documented same-gene pathogenic variant, phase, or Fanconi Anemia phenotype is available to assign PM3 points. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 specification limits PM3 to a patient with a phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia and a co-occurrent variant in the same gene. The case evidence bundle contains no documented pathogenic or likely pathogenic BRCA1 variant in the same patient, phase or trans/cis determination, affected-proband observation, chromosome-breakage result, or Fanconi Anemia phenotype meeting the VCEP requirements. Therefore no PM3-related points can be assigned and PM3 is not assessed. The exact target variant was not found in Specifications_V1.2_2024-11-18.docx.txt; the p.T77= entries found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt refer to c.231G>T, not NM_007294.4:c.231G>A.

VCEP rule
Apply for patient with phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia (FA), and co-occurrent variants in the same gene. ... See Table 6 for approach to assign points per proband, and final PM3 code assignment based on the sum of PM3-related points.
Evidence considered
  • The case evidence bundle identifies the assessed allele as NM_007294.4:c.231G>A / NP_009225.1:p.(Thr77=), but provides no qualifying PM3 co-occurrence, phase, affected-proband, or Fanconi Anemia phenotype evidence.
  • Specifications_V1.2_2024-11-18.docx.txt, PM3 rule and Table 6: PM3 points require a qualifying BRCA1-related Fanconi Anemia patient with a P or LP variant in trans, homozygote, or phase unknown; no target-allele PM3 record was found in this file.
  • Specifications_Table9_V1.2_2024-11-18.xlsx.txt, matching p.T77= row: c.231G>T, not c.231G>A; this is not evidence for PM3 for the assessed allele.
Still missing
  • No affected-proband observation with a qualifying Fanconi Anemia phenotype is documented.
  • No same-gene pathogenic or likely pathogenic co-occurrent variant is documented.
  • No phase evidence establishing trans, cis, homozygosity, or phase-unknown co-occurrence is documented.
  • No chromosome-breakage result or qualifying physical, pathology/laboratory, or cancer diagnosis by age 5 evidence is documented.
  • No exact NM_007294.4:c.231G>A, p.Thr77=, or p.T77= target entry was found in Specifications_V1.2_2024-11-18.docx.txt; the p.T77= hit in Specifications_Table9_V1.2_2024-11-18.xlsx.txt is c.231G>T, not the assessed allele.
Sources
PP1 VCEPNot assessed: no quantitative co-segregation LR, affected-family pedigree, or informative meioses are available for this variant. Details ▾Hide ▴
Reasoning

The VCEP requires co-segregation with disease in multiple affected family members measured by a quantitative co-segregation method and assigns strength from the resulting LR. The available case evidence contains no documented affected-family pedigree, informative meioses, parental testing, or quantitative co-segregation LR for NM_007294.4:c.231G>A; therefore PP1 cannot be evaluated without substituting non-VCEP assumptions.

VCEP rule
Co-segregation with disease in multiple affected family members ... Apply weight as per Bayes Score: ... PP1 - LR ≥2.08:1 ... PP1_Moderate – LR≥4.3:1 ... PP1_Strong – LR≥18.7:1 ... PP1_Very Strong – LR≥350:1
Evidence considered
  • The case evidence bundle provides no variant-specific affected-relative segregation observations, parental genotypes, meioses count, pedigree, or quantitative co-segregation result for NM_007294.4:c.231G>A.
  • The VCEP Appendix I states that the preferred analysis is Bayesian and that the Bayes score directly measures evidence across available family evidence; no such score is present for this variant.
Still missing
  • No affected-family segregation dataset, parental testing results, informative meioses, or quantitative co-segregation LR is available in the case evidence bundle for NM_007294.4:c.231G>A.
  • Searched HUMU-40-1557-s001.xlsx full text for c.231G>A, p.Thr77=, and p.T77=; no matching entry was found.
Sources
BA1 VCEPNot assessed: the governing rule requires non-founder FAF above 0.001 and at least 20× read depth, but neither FAF nor depth is reported. Details ▾Hide ▴
Reasoning

The ENIGMA rule requires a non-founder filter allele frequency (FAF) above 0.001 in the specified non-cancer datasets, with read depth at least 20. The available gnomAD v2.1 non-cancer exome record reports AF 4.225042672930997e-06 (1/236684 alleles; homozygotes 0) and no FAF or read-depth value; gnomAD v3.1 non-cancer is absent. The available values therefore do not demonstrate the BA1 threshold, but the governing FAF and read-depth requirements cannot be fully evaluated.

VCEP rule
Filter allele frequency (FAF) is above 0.1% (FAF > 0.001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • gnomAD v2.1 non-cancer exomes: c.231G>A is present at AF 4.225042672930997e-06, 1/236684 alleles, with 0 homozygotes; the record reports no FAF or read-depth value.
  • gnomAD v3.1 non-cancer: variant record absent; no FAF is available from that specified dataset.
  • The all-comers gnomAD v4.1 grpmax FAF of 1.24e-06 was not substituted because the governing VCEP rule specifies gnomAD v2.1 non-cancer exomes and/or gnomAD v3.1 non-cancer genomes.
Still missing
  • No FAF or regional read-depth value is reported for the gnomAD v2.1 non-cancer exome record.
  • No gnomAD v3.1 non-cancer variant record is present, so no v3.1 FAF can be evaluated.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
BS1 VCEPNot assessed: the governing rule requires non-founder FAF above 0.00002 and at least 20× read depth, but neither FAF nor depth is reported. Details ▾Hide ▴
Reasoning

The ENIGMA rule requires a non-founder FAF above 0.0001 for BS1 or above 0.00002 and at most 0.0001 for BS1_Supporting, in the specified non-cancer datasets, with read depth at least 20. The available gnomAD v2.1 non-cancer exome record reports AF 4.225042672930997e-06 (1/236684 alleles; homozygotes 0) and no FAF or read-depth value; gnomAD v3.1 non-cancer is absent. The available values do not demonstrate either BS1 threshold, but the governing FAF and read-depth requirements cannot be fully evaluated.

VCEP rule
Filter allele frequency (FAF) is above 0.01% (FAF > 0.0001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details. ... Filter allele frequency (FAF) is above 0.002% (FAF > 0.00002) and less than or equal to 0.01% (FAF ≤ 0.0001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • gnomAD v2.1 non-cancer exomes: c.231G>A is present at AF 4.225042672930997e-06, 1/236684 alleles, with 0 homozygotes; the record reports no FAF or read-depth value.
  • gnomAD v3.1 non-cancer: variant record absent; no FAF is available from that specified dataset.
  • The all-comers gnomAD v4.1 values were not substituted because the governing VCEP rule specifies gnomAD v2.1 non-cancer exomes and/or gnomAD v3.1 non-cancer genomes.
Still missing
  • No FAF or regional read-depth value is reported for the gnomAD v2.1 non-cancer exome record.
  • No gnomAD v3.1 non-cancer variant record is present, so no v3.1 FAF can be evaluated.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
BS2 VCEPNot assessed: no phenotyped clinical-cohort co-occurrence or homozygote observation meeting the VCEP's Fanconi-Anemia-unaffected points table is available. Details ▾Hide ▴
Reasoning

The ENIGMA BS2 rule requires observations of the variant in trans with a pathogenic or likely pathogenic variant, or as a homozygote, in phenotyped clinical or research-cohort individuals without the specified Fanconi Anemia phenotype, with points assigned by age or cancer follow-up. The available evidence contains no such clinical-cohort observation, phase information, cancer age or follow-up, or phenotype assessment. The gnomAD record has zero homozygotes, and the VCEP explicitly excludes frequency-based data from BS2.

VCEP rule
Applied in absence of features of recessive disease, namely Fanconi Anemia phenotype. See **Specifications Table 8** for additional stipulations, and approach to assign points per proband, and final BS2 code assignment based on the sum of BS2-related points. See Appendix H for additional details. ... BS2 = ≥ 4 points
Evidence considered
  • gnomAD v2.1 non-cancer exomes reports 0 homozygotes for c.231G>A; gnomAD frequency data cannot be used for BS2 under the VCEP's phenotyped-cohort stipulation.
  • The case evidence contains no clinical or research-cohort co-occurrence, phase, age/follow-up, or Fanconi Anemia phenotype data for this variant.
Still missing
  • No phenotyped clinical or research-cohort observation in trans with a P/LP variant, or as a homozygote, is available.
  • No phase, age at first cancer, age at last follow-up, or Fanconi Anemia phenotype assessment is available.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
BS3 VCEPNot assessed: no exact c.231G>A functional-assay entry or pre-assigned BS3 code was found in the governing ENIGMA datasets. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_007294.4:c.231G>A; p.(Thr77=)/p.(T77=)). The governing ENIGMA functional-assay sources were searched under c.231G>A, p.Thr77=, and p.T77=. Specifications Table 9 contains no exact entry for this variant, and Supplementary Tables ST4 contains no exact functional-assay row. The nearby but different synonymous variants c.231G>C and c.231G>T are not evidence for c.231G>A and were not transferred. The VCEP BS3 rule requires well-established functional studies showing no damaging effect on protein function, measured via protein alone or combined mRNA and protein; the available governing record does not provide variant-specific assay evidence or a pre-assigned BS3 code for c.231G>A. Therefore BS3 cannot be assessed from the permitted evidence.

VCEP rule
Well-established in vitro or in vivo functional studies shows no damaging effect on protein function. Assay measures effect via protein only OR mRNA and protein combined. See Specifications Table 9 for code recommendations from calibrated published assays.
Evidence considered
  • Specifications Table 9, searched rows for c.231G>A, p.Thr77=, and p.T77=: no exact row; the table states that listed calibrated functional results carry code recommendations, but this variant is not listed.
  • Supplementary Tables ST4, searched rows for c.231G>A, p.Thr77=, and p.T77=: no exact row. Nearby distinct variants c.231G>C (FUNC) and c.231G>T (LOF) were not used for this variant.
  • Specifications v1.2, BS3 functional-assay rule: no-damaging-effect studies are assessed under BS3 when the assay measures protein alone or mRNA and protein combined; no qualifying variant-specific result was available.
  • Appendices v1.2, Appendix E / PS3 and BS3 code-use material: functional evidence must be evaluated using the VCEP functional-assay process and calibrated data; no exact c.231G>A result was identified.
  • HUMU-40-1557-s001, searched for c.231G>A and related synonymous notation: no exact functional-assay classification row was identified.
Still missing
  • No exact c.231G>A entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt after searches for c.231G>A, p.Thr77=, and p.T77=.
  • No exact c.231G>A entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt after searches for c.231G>A, p.Thr77=, and p.T77=.
  • No variant-specific protein-only or combined mRNA/protein assay result showing no damaging effect for c.231G>A was identified in the permitted VCEP materials.
Sources
BS4 VCEPNot assessed: no quantitative non-segregation LR, affected-family pedigree, or informative meioses are available for this variant. Details ▾Hide ▴
Reasoning

The VCEP requires lack of segregation in affected family members measured by a quantitative co-segregation method and assigns strength from the resulting LR. The available case evidence contains no documented non-segregating affected relatives, informative meioses, parental testing, or quantitative non-segregation LR for NM_007294.4:c.231G>A; therefore BS4 cannot be evaluated without substituting non-VCEP assumptions.

VCEP rule
Lack of segregation in affected members of a family. ... Apply weight as per Bayes Score: ... BS4_Supporting - LR ≤0.48 to >0.23:1 ... BS4_Moderate - LR ≤0.23:1 ... BS4 - LR ≤0.05:1 ... BS4_Very strong – LR ≤0.00285:1
Evidence considered
  • The case evidence bundle provides no variant-specific affected-relative non-segregation observations, parental genotypes, meioses count, pedigree, or quantitative co-segregation result for NM_007294.4:c.231G>A.
  • The VCEP Appendix I states that Bayes scores can be converted to BS4 strength categories, but no variant-specific Bayes score or LR is present for this case.
Still missing
  • No affected-family non-segregation dataset, parental testing results, informative meioses, or quantitative non-segregation LR is available in the case evidence bundle for NM_007294.4:c.231G>A.
  • Searched HUMU-40-1557-s001.xlsx full text for c.231G>A, p.Thr77=, and p.T77=; no matching entry was found.
Sources
Not applicable · 11· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.231G>A is synonymous (p.Thr77=), not one of the VCEP-defined null variants, and SpliceAI max delta 0.052 is below 0.2. Details ▾Hide ▴
Reasoning

NM_007294.4:c.231G>A is a synonymous variant, NP_009225.1:p.(Thr77=), in exon 5, not a nonsense, frameshift, canonical donor/acceptor splice-site, initiation-codon, or exon-deletion null variant. SpliceAI max delta is 0.052, below the VCEP's predicted-splicing threshold of 0.2, and the governing VCEP rule limits PVS1 to the named null-variant classes. The ENIGMA Table 4 BRCA1 E5(6) row assigns PVS1 to PTC and designated splice/deletion paths, none of which describes this variant.

VCEP rule
Null variant (nonsense, frameshift, splice site (donor/acceptor +/−1,2), initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease. Apply at appropriate strength according to PVS1 flowchart, which considers knowledge of clinically important functional domains. See Specifications Table 4 and Appendix D for details.
Evidence considered
  • Variant assessment: NM_007294.4:c.231G>A; NP_009225.1:p.(Thr77=); synonymous consequence; exon 5.
  • SpliceAI result for NM_007294.4:c.231G>A: max delta score 0.052.
  • ENIGMA Specifications Table 4, BRCA1 E5(6) row: PVS1 is assigned for the PTC and specified splice/deletion paths; this synonymous c.231G>A variant is not one of those paths.
Sources
PS1 N/ANot applicable: c.231G>A is synonymous, and SpliceAI max delta 0.052 is below the VCEP's 0.1 no-splicing threshold. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_007294.4:c.231G>A; p.Thr77=), not a predicted missense substitution, and SpliceAI predicts no significant splice impact (maximum delta score 0.052, below 0.1). Therefore neither the VCEP's missense PS1 route nor its same-predicted-splicing route applies.

VCEP rule
Apply **PS1**, for predicted **missense** substitutions, where a previously classified **pathogenic** variant is considered to act via protein change (no confirmed or predicted effect on mRNA splicing (SpliceAI≤0.1)). ... Apply **PS1**, for exonic and intronic variants with same predicted impact on **splicing**, as a previously classified **pathogenic** variant. Vary weight depending on relative positions, and confidence in classification of the reference variant.
Evidence considered
  • Case normalization: NM_007294.4:c.231G>A produces NP_009225.1:p.(Thr77=), a synonymous substitution.
  • SpliceAI result: maximum delta score = 0.052, so the variant is below the VCEP's SpliceAI≤0.1 no-splicing boundary.
  • The governing VCEP PS1 rule is restricted to predicted missense substitutions or exonic/intronic variants with the same predicted splicing impact as a previously classified (likely) pathogenic variant; no applicable route exists for this synonymous, non-spliceogenic variant.
Sources
PS2 VCEPNot applicable: the BRCA1 VCEP explicitly says PS2 should not be used because de novo cancer occurrences lack calibration. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP specification explicitly states that PS2 is not to be used because BRCA1/2-related cancers occur relatively commonly and the predictive capacity of de novo occurrences has not been calibrated. This criterion is therefore not applicable regardless of whether de novo or parental evidence is available.

VCEP rule
De novo (paternity confirmed) in a patient with the disease and no family history. ... Do not use ... BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • ENIGMA BRCA1 specification Table 1 states: PS2, de novo with paternity confirmed in a patient with disease and no family history, Do not use; the stated reason is that BRCA1/2-related cancers occur relatively commonly and de novo occurrences are not calibrated.
Sources
PM1 VCEPNot applicable: the ENIGMA VCEP explicitly says PM1 is not used and treats this evidence within PP3/BP4 instead. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly says not to use PM1 and instead considers this evidence as part of PP3/BP4. No PM1 code is therefore applicable, regardless of residue 77 lying within the RING domain (aa 2-101).

VCEP rule
Located in a mutational hot spot and/or critical and well-established functional domain. ... Do not use ... Considered as component of bioinformatic analysis (PP3/BP4).
Evidence considered
  • The VCEP PM1 specification states: Do not use; considered as a component of bioinformatic analysis (PP3/BP4).
  • The VCEP domain definition identifies the BRCA1 RING domain as residues 2-101, placing residue 77 within that domain, but this does not restore PM1 applicability under the governing rule.
Sources
PM4 VCEPNot applicable: the variant causes no protein-length change, and the VCEP explicitly marks PM4 Do not use. Details ▾Hide ▴
Reasoning

The variant is synonymous and does not change protein length. Independently, the ENIGMA BRCA1/2 specification explicitly states that PM4 is not to be used and that protein-length changes are considered as a component of bioinformatic analysis rather than assigned PM4.

VCEP rule
Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants. ... Do not use ... Considered as component of bioinformatic analysis (PP3/BP4).
Evidence considered
  • Variant normalization: NP_009225.1:p.(Thr77=), confirming no protein-length change.
  • ENIGMA Specifications v1.2, Table 1 PM4 row: protein-length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants; Do not use; considered as a component of bioinformatic analysis (PP3/BP4).
Sources
PM5 N/ANot applicable: c.231G>A is synonymous, while VCEP PM5 is not used for missense changes and PM5(PTC) requires a PVS1 protein-termination variant. Details ▾Hide ▴
Reasoning

The VCEP explicitly does not use missense PM5 and redirects it to PP3/BP4. The repurposed PM5(PTC) route applies only to protein-termination-codon variants annotated as PVS1; c.231G>A is synonymous and is not a PTC variant.

VCEP rule
Missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before. ... Do not use ... Considered as component of bioinformatic analysis (PP3/BP4). ... Protein termination codon (PTC) variant in an exon where a different proven pathogenic PTC variant has been seen before ... Use to justify additional weight for PTC variants annotated as PVS1.
Evidence considered
  • The VCEP specification says missense PM5 is not used and is considered as a component of PP3/BP4.
  • The VCEP's repurposed PM5(PTC) rule is limited to a protein termination codon variant in an exon with a different proven pathogenic PTC variant and is used for PTC variants annotated as PVS1.
  • Case consequence: c.231G>A is synonymous, p.Thr77=, not a protein-termination-codon variant.
Sources
PM6 VCEPNot applicable: the BRCA1 VCEP explicitly says PM6 should not be used because de novo cancer occurrences lack calibration. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP specification explicitly states that PM6 is not to be used because BRCA1/2-related cancers occur relatively commonly and the predictive capacity of de novo occurrences has not been calibrated. This criterion is therefore not applicable regardless of whether parental testing is reported.

VCEP rule
Confirmed de novo without confirmation of paternity and maternity. ... Do not use ... BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • ENIGMA BRCA1 specification Table 1 states: PM6, confirmed de novo without confirmation of paternity and maternity, Do not use; the stated reason is that BRCA1/2-related cancers occur relatively commonly and de novo occurrences are not calibrated.
Sources
PP2 VCEPNot applicable: the VCEP explicitly says PP2 is not used because BRCA1 has a high frequency of benign missense variants. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly says not to use PP2 because of the high frequency of benign missense variants; the present variant is also synonymous rather than missense.

VCEP rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. ... Do not use ... High frequency of benign missense variants.
Evidence considered
  • The VCEP PP2 specification states: Do not use; high frequency of benign missense variants.
  • The case variant is synonymous (p.Thr77=), not missense.
Sources
PP5 VCEPNot applicable: the ENIGMA VCEP prohibits PP5, so no reputable-source classification can be used for this criterion. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1/2 VCEP explicitly prohibits use of PP5. This criterion is not applicable regardless of the ClinVar expert-panel Likely benign classification or other reputable-source reports.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ENIGMA BRCA1/2 VCEP CSPEC PP5 entry states: This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
  • The governing specification Table 1 lists PP5 as Do not use.
Sources
BP2 VCEPNot applicable: the ENIGMA specification explicitly states that BP2 is not to be used. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 specification lists BP2 for observations in trans or cis with a pathogenic variant, but explicitly states that BP2 is not to be used and is applied only in the context of BS2. Under the VCEP-only framework, BP2 is therefore not applicable regardless of whether phase or co-occurrence evidence is available.

VCEP rule
Do not use ... Applied only in the context of BS2.
Evidence considered
  • Specifications_V1.2_2024-11-18.docx.txt, BP2 entry: 'Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder, or observed in cis with a pathogenic variant in any inheritance pattern' followed by 'Do not use' and 'Applied only in the context of BS2.'
  • The case evidence bundle was checked for phase and co-occurrence information, but the VCEP's explicit BP2 prohibition controls the criterion disposition.
Still missing
  • No exact NM_007294.4:c.231G>A, p.Thr77=, or p.T77= target entry was found in Specifications_V1.2_2024-11-18.docx.txt; the p.T77= hit in Specifications_Table9_V1.2_2024-11-18.xlsx.txt is c.231G>T, not the assessed allele.
Sources
BP3 VCEPNot applicable: c.231G>A is synonymous, not an in-frame indel, and the VCEP explicitly marks BP3 Do not use. Details ▾Hide ▴
Reasoning

The variant is synonymous, not an in-frame deletion or insertion in a repetitive region. The ENIGMA BRCA1/2 specification explicitly marks BP3 as not to be used and states that this evidence is captured by bioinformatic tool prediction and domain analysis.

VCEP rule
In-frame deletions/insertions in a repetitive region without a known function ... Do not use ... Captured by bioinformatic tool prediction, and domain analysis.
Evidence considered
  • Variant normalization: NM_007294.4:c.231G>A; NP_009225.1:p.(Thr77=); synonymous consequence, not an in-frame deletion or insertion.
  • ENIGMA Specifications v1.2, Table 1 BP3 row: in-frame deletions/insertions in a repetitive region without a known function; Do not use; captured by bioinformatic tool prediction and domain analysis.
  • ENIGMA Appendices v1.2, BP3 section: N/A; captured by bioinformatic tool prediction and domain analysis.
Sources

Identifiers

Gene
BRCA1
Transcript
NM_007294.4
Coding (HGVS c.)
NM_007294.4:c.231G>A
Protein (HGVS p.)
NP_009225.1:p.(Thr77=)
GRCh38
chr17:43104938 C>T
GRCh37
chr17:41256955 C>T
Location and type
Exon 5 · synonymous
ClinVar
756892, 142611
COSMIC
COSV58792582

Gene diagram

Every interpreted variant in BRCA1, mapped onto the exon structure of NM_007294.4. Select a row to find it on the plot.

BRCA1NM_007294.4
Fetching transcript structure from UCSC…
gnomAD v4.1 6 / 1,613,712 alleles AF 3.72e-06 · 0 homozygotes · FAF 1.24e-06
gnomAD v2.1 1 / 251,192 alleles AF 3.98e-06 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 3.7e-06 · 6 / 1,613,712 alleles · 0 hom · FAF 1.2e-06
Admixed American1 / 59,988 1.7e-05
European (non-Finnish)5 / 1,179,898 4.2e-06
0 alternate alleles recorded in 8 other groups: Remaining individuals, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

gnomAD v2.1

AF 4e-06 · 1 / 251,192 alleles · 0 hom
Admixed American1 / 34,588 2.9e-05
0 alternate alleles recorded in 7 other groups: African/African American, Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), Remaining individuals, South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 3.71814e-06; MAF= 0.00037%, 6/1613712 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 1.667e-05; MAF= 0.00167%, 1/59988 alleles, homozygotes = 0); grpmax FAF= 1.24e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98102e-06; MAF= 0.00040%, 1/251192 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 2.89118e-05; MAF= 0.00289%, 1/34588 alleles, homozygotes = 0).

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +18 bp
0.008
SpliceAI acceptor gainat -52 bp
0.001
SpliceAI donor lossat -70 bp
0.052
SpliceAI donor gainat -61 bp
0.004
Pangolin splice lossmagnitude shown
-0.030
Pangolin splice gain
0.013

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

BP4 SupportingVCEPMet at Supporting: SpliceAI maximum delta score 0.052 is below the VCEP BP4 threshold of 0.1 for a silent variant inside the RING domain. Details ▾Hide ▴
Reasoning

The variant is synonymous and encodes p.(Thr77=), placing it at BRCA1 residue 77 within the VCEP-defined RING functional domain (aa 2-101). The VCEP BP4 rule specifically covers silent variants inside a clinically important functional domain when SpliceAI is <=0.1. The maximum SpliceAI delta score is 0.052, which meets the <=0.1 requirement; BP4 is therefore met at Supporting strength. No exact c.231G>A, p.Thr77=, or p.T77= entry was found in the searched VCEP supplementary or assay tables, and no exact mention was found in the Houdayer paper.

VCEP rule
Silent variant inside a (potentially) clinically important functional domain, if no predicted impact via splicing (SpliceAI ≤0.1).
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 CSPEC BP4 rule: silent variants inside a potentially clinically important functional domain qualify when SpliceAI <=0.1.
  • The VCEP defines the BRCA1 RING functional domain as amino acids 2-101; p.(Thr77=) is within this domain.
  • Case SpliceAI result for NM_007294.4:c.231G>A: maximum delta score 0.052 (DS_DL 0.052), meeting the VCEP BP4 threshold.
  • Variant normalization identifies NM_007294.4:c.231G>A as synonymous, NP_009225.1:p.(Thr77=).
  • SupplementaryTables_V1.2_2024-11-18.xlsx.txt and Specifications_Table9_V1.2_2024-11-18.xlsx.txt were searched under c.231G>A, p.Thr77=, and p.T77=; neither contained an exact matching row.
  • PMID_22505045_Houdayer_2012_HumMutat.pdf.txt was searched for the variant notations and contained no exact match.
Still missing
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= mention was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BP7 SupportingVCEPMet at Supporting: the silent p.(Thr77=) variant meets BP4 with SpliceAI maximum delta score 0.052, satisfying the VCEP BP7 condition. Details ▾Hide ▴
Reasoning

The variant is a silent substitution at p.(Thr77=), within the VCEP-defined BRCA1 RING domain (aa 2-101). The VCEP assigns BP7 at Supporting strength to a silent variant inside a clinically important functional domain if BP4 is met. BP4 is met because the SpliceAI maximum delta score is 0.052, no greater than 0.1; BP7 is consequently met at Supporting strength. The VCEP explicitly states that BP7 is applied in addition to BP4 for silent variants. No exact c.231G>A, p.Thr77=, or p.T77= entry was found in the searched VCEP tables or Houdayer paper.

VCEP rule
Silent variant inside a (potentially) clinically important functional domain, IF BP4 met.
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 CSPEC BP7 rule: silent variant inside a potentially clinically important functional domain qualifies if BP4 is met.
  • The VCEP defines the BRCA1 RING functional domain as amino acids 2-101; p.(Thr77=) is within this domain.
  • BP4 is met from the case SpliceAI maximum delta score of 0.052, which is <=0.1 under the VCEP rule.
  • The VCEP states that BP7 is applied in addition to BP4 for silent variants.
  • SupplementaryTables_V1.2_2024-11-18.xlsx.txt and Specifications_Table9_V1.2_2024-11-18.xlsx.txt were searched under c.231G>A, p.Thr77=, and p.T77=; neither contained an exact matching row.
  • PMID_22505045_Houdayer_2012_HumMutat.pdf.txt was searched for the variant notations and contained no exact match.
Still missing
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= mention was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
PP3 VCEPNot met: SpliceAI maximum delta score 0.052 is below the VCEP PP3 threshold of 0.2 for predicted splicing in silent variants. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_007294.4:c.231G>A; p.(Thr77=)) and therefore falls within the VCEP's PP3 splicing path. The governing rule requires SpliceAI >=0.2 for PP3 on silent variants. The available SpliceAI maximum delta score is 0.052 (DS_DL 0.052), below that threshold, so PP3 is not met. No exact c.231G>A, p.Thr77=, or p.T77= entry was found in the governing supplementary lookup file or the searched VCEP assay tables; the c.231G>C and c.231G>T rows are different variants and were not used.

VCEP rule
Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions.
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 CSPEC PP3 rule: predicted splicing applies to silent variants at SpliceAI >=0.2.
  • Case SpliceAI result for NM_007294.4:c.231G>A: DS_AG 0.001, DS_AL 0.008, DS_DG 0.004, DS_DL 0.052; maximum delta score 0.052.
  • Variant normalization identifies NM_007294.4:c.231G>A as synonymous, NP_009225.1:p.(Thr77=).
  • SupplementaryTables_V1.2_2024-11-18.xlsx.txt was searched for c.231G>A, p.Thr77=, and p.T77=; only different c.231G>C and c.231G>T rows were found.
  • Specifications_Table9_V1.2_2024-11-18.xlsx.txt was searched for c.231G>A, p.Thr77=, and p.T77=; no exact matching row was found.
  • PMID_22505045_Houdayer_2012_HumMutat.pdf.txt was searched for c.231G>A, p.Thr77=, p.T77=, and T77; no exact variant mention was found.
Still missing
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • No exact c.231G>A, p.Thr77=, or p.T77= mention was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.05).

8 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants.
    Houdayer C et al. · 2012
    The searched full text does not mention BRCA1 c.231G>A, p.Thr77=, p.T77=, or T77; it therefore provides no variant-specific splicing result for this case.
    Does not name this variant
    PMID 22505045 ↗
  • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    No paper-specific finding is recorded.
    PMID 23918944 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    The paper does not mention BRCA1, c.231G>A, NP_009225.1:p.(T77=), or any BRCA1-specific functional, clinical, segregation, or population data. It provides general ACMG/AMP guidance but reports no experimental or case-control result for this variant.
    Does not name this variant
    PMID 25741868 ↗
    Quoted passage
    Assays that assess the impact of variants at the mRNA level can be highly informative when evaluating the effects of variants at splice junctions and within coding sequences, untranslated regions, as well as deeper intronic regions (e.g. mRNA stability, processing or translation).

    Proposed Criteria for Interpretation of Sequence Variants, PS3/BS3 Functional studies

  • BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301425 ↗
  • ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
    The paper does not explicitly mention BRCA1, c.231G>A, or NP_009225.1:p.(T77=). It provides no variant-specific functional assay results, case observations, segregation data, population-frequency data, or BRCA1-specific mechanistic information; its discussion is limited to general recommendations for reporting incidental findings from clinical sequencing, including cancer-susceptibility genes.
    Does not name this variant
    PMID 23788249 ↗
  • A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
    Hampel H et al. · 2015
    No paper-specific finding is recorded.
    PMID 25394175 ↗
  • Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Versi
    No paper-specific finding is recorded.
    PMID 26389258 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 3.71814e-06; MAF= 0.00037%, 6/1613712 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 1.667e-05; MAF= 0.00167%, 1/59988 alleles, homozygotes = 0); grpmax FAF= 1.24e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98102e-06; MAF= 0.00040%, 1/251192 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 2.89118e-05; MAF= 0.00289%, 1/34588 alleles, homozygotes = 0).

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Likely benign (7 clinical laboratories) and as Likely Benign (1 clinical laboratory) and as Likely benign by Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) (expert panel). (ClinVarID = 142611)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.05).

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV58792582, n = 4 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.